Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

The Use of GnRH Agonists in Feminizing Hormone Therapy Does Not Lead to Negative Metabolic or Bone Health Outcomes in Adult Transgender Women

  • By

  • Brunet, Louise

  • Busiah, Kanetee

  • Moser, Mireille

  • Papadakis, Georgios E.

  • May 21, 2026

Share

Original Source(s)

Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women

  • by Brunet, Louise , Busiah, Kanetee , Moser, Mireille , Papadakis, Georgios E.

  • May 21, 2026

Related Content

Low Caregiver State Anxiety is Associated with Worse Glycemic Control in Youth with Type 1 Diabetes Mellitus: A Cross-Sectional Study

Secular trends in HbA1c levels among children and adolescents with type 1 diabetes

Dietary Inflammatory Potential and Cardiometabolic Risk Factors in School-Aged Adolescents